ReviewOncoTargets and therapy2020
The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer.
Review in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Diagnostic and prognostic role of NLR in testicular cancer.Exploration of targeted anti-tumor therapy · 2024Pooled it
- Predictive Role of Serum Inflammatory Markers in Metastatic Luminal A/B Breast Cancers Receiving CDK-4/6 Inhibitors Therapy.Immunity, inflammation and disease · 2026Article
- Neoadjuvant camrelizumab in combination with chemotherapy followed by sequential radical surgery for locally advanced esophageal squamous cell carcinoma: postoperative pathological remission characteristics and influencing factors.Frontiers in oncology · 2026Article
- Explainable machine learning for breast mass characterization and malignancy risk stratification: multimodal integration of AI-derived structured digital breast tomosynthesis features and peripheral blood immune-inflammatory biomarkers.Frontiers in cell and developmental biology · 2026Article
- Robust Association of Breast Cancer Co-morbidity Using Subtype-specific Expressed Genes.Current drug targets · 2026Article
- The Hematological Variations and Effect of Cadmium Induced Toxicity on Mammary Tumors Development in Albino Mice. A Comparative Model Study on the Effect of Heavy Metals in Human Breast Cancer.Anti-cancer agents in medicinal chemistry · 2026Article
- The Lymphocyte-to-Monocyte Ratio (LMR) as a Novel Biomarker for Cervical Cancer Risk Stratification in Conization Patients.Journal of clinical medicine · 2025Article
- Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes.Scientific reports · 2025Article
- PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors.International journal of clinical oncology · 2025Article
- The association and clinical significance of hematological biomarkers in ankylosing spondylitis.Scientific reports · 2025Article
- Development and validation of a prediction model for recurrence based on ProMisE molecular classifier and immune-inflammatory- nutritional score in endometrial carcinoma: a retrospective multiple-center study.International journal of medical sciences · 2025Article
- Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study.Thoracic cancer · 2025Observational
- Clinical Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte Index (CALLY) in Patients with Stage III Breast Cancer.Breast cancer (Dove Medical Press) · 2025Article
- Development of predictive models for pathological response status in breast cancer after neoadjuvant therapy based on peripheral blood inflammatory indexes.BMC women's health · 2024Article
- The predictive value of serum inflammatory markers for the severity of cervical lesions.BMC cancer · 2024Article
- A novel machine learning prediction model for metastasis in breast cancer.Cancer reports (Hoboken, N.J.) · 2024Article
- Comparison of Hematological Parameters and the Associated Factors Among Women with and without Breast Cancer: A Case-Control Study.Breast cancer (Dove Medical Press) · 2024Article
- Thromboelastogram and coagulation function index: relevance for female breast cancer.Frontiers in oncology · 2024Article
- A novel nomogram based on the hematological prognosis risk scoring system can predict the overall survival of patients with hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study.Nutrients · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast carcinoma is one of the most malignant tumors, severely influencing the physical and mental health of people. The latest epidemiological and clinical studies have found that breast tumor and inflammation are determinate relationships with each other. Inflammation is an essential component of the tumor microenvironment, and the change of inflammatory cells might influence tumor progression, such as neoplastic cell proliferation, migration, invasion, the collapse of antitumor immunity, metastasis and so forth. Peripheral blood tests at the time of diagnosis and treatment can reflect inflammatory conditions within the neoplasm. Evaluation of peripheral blood parameters including white blood cell, neutrophil, lymphocyte, monocyte, platelet counts, as well as neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (d-NLR) (neutrophil count divided by the result of white blood cell count minus neutrophil count), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR), which are indicators of systematic inflammatory response, have been widely proposed as prognostic factors for many malignancies. To intensively study the relationship between the common markers in peripheral blood and the treatment or prognosis of breast cancer will have critical clinical significance and application prospect, and can provide useful information for the clinicians. Herein, we review the research progress in the prognostic role of the peripheral blood in breast cancer to provide a new method for the treatment and prognosis of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.